Sulaiman Olaide Bukky
Sulaiman Olaide Bukky has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Emmanuel Kokori
University of Ilorin, Ilorin, Nigeria
4 shared publications - Gbolahan Olatunji
Department of Medicine and Surgery, University of Ilorin, Ilorin, Nigeria
4 shared publications - Israel Charles Abraham
University of Ilorin, Ilorin, Nigeria
4 shared publications - Nicholas Aderinto
Ladoke Akintola University of Technology, Ogbomosho, Nigeria
4 shared publications - Adetola Emmanuel Babalola
Kornberg School of Dentistry, Temple University, Philadelphia, USA
2 shared publications - Florence Oluwatoyin Akintepede
Department of Medicine and Surgery, Ladoke Akintola University of Technology, Ogbomoso, Nigeria
2 shared publications
Latest Publications
- Open Access
- 27 November 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 569-579
Efficacy and safety of dual-task training in enhancing cognitive and motor recovery for post-stroke rehabilitation
Stroke is a leading cause of disability and mortality worldwide, with survivors frequently experiencing motor and cognitive impairments that hinder their daily functioning and independence. Dual-task training (DTT), an innovative rehabilitation approach, targets simultaneous improvement in motor and cognitive functions by addressing cognitive-motor interference. This narrative review evaluates the efficacy and safety of DTT in poststroke rehabilitation. PubMed, Google Scholar, Cochrane Library, Scopus, and the Directory of Open Access Journals were searched, yielding 31 studies, including randomized controlled trials and observational studies. Articles were identified that evaluated the safety and efficacy of DTT for poststroke rehabilitation in patients who had suffered from hemorrhagic or ischemic stroke. Before extracting variables, the studies were imported into Rayyan software, and thematic analysis was subsequently conducted using Microsoft Excel. The findings indicate that DTT enhances gait parameters, balance, and cognitive functions, particularly attention and executive function. Additionally, it improves functional outcomes, including activities of daily living, and reduces fall risk. While DTT demonstrates promise in fostering neuroplasticity and improving recovery outcomes, questions regarding its long-term efficacy, optimal implementation, and safety warrant further investigation. This review highlights the potential of DTT as a promising approach in stroke rehabilitation, supporting more integrated recovery strategies.
- 27 November 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 569-579
Open AccessEfficacy and safety of dual-task training in enhancing cognitive and motor recovery for post-stroke rehabilitation
Stroke is a leading cause of disability and mortality worldwide, with survivors frequently experiencing motor and cognitive impairments that hinder their daily functioning and independence. Dual-task training (DTT), an innovative rehabilitation approach, targets simultaneous improvement in motor and cognitive functions by addressing cognitive-motor interference. This narrative review evaluates the efficacy and safety of DTT in poststroke rehabilitation. PubMed, Google Scholar, Cochrane Library, Scopus, and the Directory of Open Access Journals were searched, yielding 31 studies, including randomized controlled trials and observational studies. Articles were identified that evaluated the safety and efficacy of DTT for poststroke rehabilitation in patients who had suffered from hemorrhagic or ischemic stroke. Before extracting variables, the studies were imported into Rayyan software, and thematic analysis was subsequently conducted using Microsoft Excel. The findings indicate that DTT enhances gait parameters, balance, and cognitive functions, particularly attention and executive function. Additionally, it improves functional outcomes, including activities of daily living, and reduces fall risk. While DTT demonstrates promise in fostering neuroplasticity and improving recovery outcomes, questions regarding its long-term efficacy, optimal implementation, and safety warrant further investigation. This review highlights the potential of DTT as a promising approach in stroke rehabilitation, supporting more integrated recovery strategies.
- Open Access
- 25 November 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 548-553
Is there hope for HER2-positive colorectal cancer with Trastuzumab? A review of current evidence
Trastuzumab combinations are emerging as a promising therapeutic strategy for HER2-positive colorectal cancer. This review investigates the current clinical data on efficacy and safety. Clinical trials have shown encouraging results, with objective response rates (ORRs) ranging from 22.2 to 46% and complete remission achievable in some patients. Additionally, these combinations demonstrate potential for improved overall survival (OS). However, optimizing therapeutic strategies remains crucial. Future research should tailor treatment regimens based on tumor biology and individual patient characteristics. Investigating ctDNA genotyping as a reliable method for identifying responders and exploring the role of Rat Sarcoma Virus (RAS) mutations and other molecular markers are key areas for optimizing patient selection and treatment efficacy. Understanding resistance mechanisms is vital for developing combination therapies that overcome these pathways.
- 25 November 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 548-553
Open AccessIs there hope for HER2-positive colorectal cancer with Trastuzumab? A review of current evidence
Trastuzumab combinations are emerging as a promising therapeutic strategy for HER2-positive colorectal cancer. This review investigates the current clinical data on efficacy and safety. Clinical trials have shown encouraging results, with objective response rates (ORRs) ranging from 22.2 to 46% and complete remission achievable in some patients. Additionally, these combinations demonstrate potential for improved overall survival (OS). However, optimizing therapeutic strategies remains crucial. Future research should tailor treatment regimens based on tumor biology and individual patient characteristics. Investigating ctDNA genotyping as a reliable method for identifying responders and exploring the role of Rat Sarcoma Virus (RAS) mutations and other molecular markers are key areas for optimizing patient selection and treatment efficacy. Understanding resistance mechanisms is vital for developing combination therapies that overcome these pathways.
- Open Access
- 15 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 8478-8485
Umbrella review of anticoagulation strategies for secondary prevention of cardioembolic stroke in atrial fibrillation: efficacy, safety, and knowledge gaps
Atrial fibrillation (AF) is a major contributor to cardioembolic stroke. Anticoagulation, guided by CHA2DS2-VASc and HAS-BLED scores, is critical for secondary prevention, yet challenges persist in timing, patient-specific tailoring, and balancing efficacy with bleeding risk. This umbrella review synthesizes evidence on anticoagulation strategies for secondary prevention of cardioembolic stroke in AF patients. We searched PubMed, Scopus, Cochrane Library, Web of Science, and Embase for systematic reviews and meta-analyses (inception to May 2025) assessing oral anticoagulants (OACs) [vitamin K antagonists (VKAs), direct oral anticoagulants (DOACs)] in AF patients with prior stroke or transient ischemic attack (TIA). Outcomes included recurrent stroke, systemic embolism, major bleeding, intracranial hemorrhage (ICH), and mortality. Quality was assessed using AMSTAR-2. Data were narratively synthesized, with quantitative metrics extracted where feasible. Eight reviews (2007–2025) were included, comprising 4–52 studies and 6893–94 656 participants. DOACs demonstrated superior efficacy over VKAs [apixaban odds ratio (OR) 0.79, 95% confidence interval (CI) 0.66–0.94], and VKAs outperformed antiplatelets (relative risk reduction 64%, absolute risk reduction 8.4%/year). DOACs showed lower major bleeding and ICH rates than VKAs, with apixaban exhibiting the most favorable safety profile (OR 0.71, 95% CI 0.61–0.81). Early versus delayed OAC initiation post-stroke improved efficacy (OR 0.68, 95% CI 0.55–0.84) with comparable safety. Identified knowledge gaps include optimal timing of OACs, outcomes in high-risk subgroups (elderly, renal impairment, and post-ICH), and cost-effectiveness. DOACs are superior to VKAs for secondary prevention of cardioembolic stroke in AF. However, individualized approaches are needed for timing and high-risk subgroups.
- 15 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 8478-8485
Open AccessUmbrella review of anticoagulation strategies for secondary prevention of cardioembolic stroke in atrial fibrillation: efficacy, safety, and knowledge gaps
Atrial fibrillation (AF) is a major contributor to cardioembolic stroke. Anticoagulation, guided by CHA2DS2-VASc and HAS-BLED scores, is critical for secondary prevention, yet challenges persist in timing, patient-specific tailoring, and balancing efficacy with bleeding risk. This umbrella review synthesizes evidence on anticoagulation strategies for secondary prevention of cardioembolic stroke in AF patients. We searched PubMed, Scopus, Cochrane Library, Web of Science, and Embase for systematic reviews and meta-analyses (inception to May 2025) assessing oral anticoagulants (OACs) [vitamin K antagonists (VKAs), direct oral anticoagulants (DOACs)] in AF patients with prior stroke or transient ischemic attack (TIA). Outcomes included recurrent stroke, systemic embolism, major bleeding, intracranial hemorrhage (ICH), and mortality. Quality was assessed using AMSTAR-2. Data were narratively synthesized, with quantitative metrics extracted where feasible. Eight reviews (2007–2025) were included, comprising 4–52 studies and 6893–94 656 participants. DOACs demonstrated superior efficacy over VKAs [apixaban odds ratio (OR) 0.79, 95% confidence interval (CI) 0.66–0.94], and VKAs outperformed antiplatelets (relative risk reduction 64%, absolute risk reduction 8.4%/year). DOACs showed lower major bleeding and ICH rates than VKAs, with apixaban exhibiting the most favorable safety profile (OR 0.71, 95% CI 0.61–0.81). Early versus delayed OAC initiation post-stroke improved efficacy (OR 0.68, 95% CI 0.55–0.84) with comparable safety. Identified knowledge gaps include optimal timing of OACs, outcomes in high-risk subgroups (elderly, renal impairment, and post-ICH), and cost-effectiveness. DOACs are superior to VKAs for secondary prevention of cardioembolic stroke in AF. However, individualized approaches are needed for timing and high-risk subgroups.
- Open Access
- 13 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 8514-8522
Impact of left atrial appendage closure on long-term stroke risk in atrial fibrillation: an umbrella review
Left atrial appendage closure (LAAC) is an alternative to oral anticoagulation (OAC) for stroke prevention in atrial fibrillation (AF). While efficacy is established for follow-up periods up to 5 years, longer-term (>5 years) stroke outcomes remain underexplored, particularly across diverse AF populations and LAAC approaches (percutaneous and surgical). This paper synthesizes systematic reviews and meta-analyses evaluating the impact of LAAC on stroke risk in AF patients, focusing on ischemic and hemorrhagic stroke, device-specific outcomes, antithrombotic regimens, and valvular vs. non-valvular AF differences. We searched PubMed, Embase, Scopus, Cochrane Library, and Web of Science for systematic reviews and meta-analyses on LAAC and stroke outcomes in AF, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. Included reviews reported stroke outcomes. Data were extracted on study characteristics, stroke outcomes, complications (e.g., device-related thrombosis), and subgroups. Quality was assessed using AMSTAR-2. Narrative synthesis was performed. Ten reviews (over 50 000 patients) were included, with follow-ups up to 5 years. LAAC reduced hemorrhagic stroke [e.g., hazard ratio 0.22, 95% confidence interval (CI) 0.08–0.61] and was non-inferior to OAC for all-cause stroke (OR 0.71, 95% CI 0.51–1.00). Surgical LAAC in valvular AF reduced stroke risk (Relative Risk (RR) 0.87, 95% CI 0.84–0.91). Complications like peri-device leaks increased ischemic stroke risk in non-valvular AF. No reviews reported >5-year stroke data. AMSTAR-2 ratings were moderate to high. LAAC effectively reduces hemorrhagic stroke risk in AF, with comparable all-cause stroke prevention to OAC up to 5 years. Longer-term (>5 years) data and valvular AF outcomes are limited, warranting further research.
- 13 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 8514-8522
Open AccessImpact of left atrial appendage closure on long-term stroke risk in atrial fibrillation: an umbrella review
Left atrial appendage closure (LAAC) is an alternative to oral anticoagulation (OAC) for stroke prevention in atrial fibrillation (AF). While efficacy is established for follow-up periods up to 5 years, longer-term (>5 years) stroke outcomes remain underexplored, particularly across diverse AF populations and LAAC approaches (percutaneous and surgical). This paper synthesizes systematic reviews and meta-analyses evaluating the impact of LAAC on stroke risk in AF patients, focusing on ischemic and hemorrhagic stroke, device-specific outcomes, antithrombotic regimens, and valvular vs. non-valvular AF differences. We searched PubMed, Embase, Scopus, Cochrane Library, and Web of Science for systematic reviews and meta-analyses on LAAC and stroke outcomes in AF, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. Included reviews reported stroke outcomes. Data were extracted on study characteristics, stroke outcomes, complications (e.g., device-related thrombosis), and subgroups. Quality was assessed using AMSTAR-2. Narrative synthesis was performed. Ten reviews (over 50 000 patients) were included, with follow-ups up to 5 years. LAAC reduced hemorrhagic stroke [e.g., hazard ratio 0.22, 95% confidence interval (CI) 0.08–0.61] and was non-inferior to OAC for all-cause stroke (OR 0.71, 95% CI 0.51–1.00). Surgical LAAC in valvular AF reduced stroke risk (Relative Risk (RR) 0.87, 95% CI 0.84–0.91). Complications like peri-device leaks increased ischemic stroke risk in non-valvular AF. No reviews reported >5-year stroke data. AMSTAR-2 ratings were moderate to high. LAAC effectively reduces hemorrhagic stroke risk in AF, with comparable all-cause stroke prevention to OAC up to 5 years. Longer-term (>5 years) data and valvular AF outcomes are limited, warranting further research.